Last reviewed · How we verify

aspirin and dipyridamole

UMC Utrecht · FDA-approved active Small molecule Quality 18/100

aspirin and dipyridamole is a Nonsteroidal Anti-inflammatory Drug [EPC] Small molecule drug developed by UMC Utrecht. It is currently FDA-approved for Stroke prevention.

Aspirin and dipyridamole, marketed by UMC Utrecht, is a well-established drug primarily indicated for stroke prevention. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-patent expiry, which could significantly impact market share and revenue.

At a glance

Generic nameaspirin and dipyridamole
SponsorUMC Utrecht
Drug classNonsteroidal Anti-inflammatory Drug [EPC]
ModalitySmall molecule
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about aspirin and dipyridamole

What is aspirin and dipyridamole?

aspirin and dipyridamole is a Nonsteroidal Anti-inflammatory Drug [EPC] drug developed by UMC Utrecht, indicated for Stroke prevention.

What is aspirin and dipyridamole used for?

aspirin and dipyridamole is indicated for Stroke prevention.

Who makes aspirin and dipyridamole?

aspirin and dipyridamole is developed and marketed by UMC Utrecht (see full UMC Utrecht pipeline at /company/umc-utrecht).

What drug class is aspirin and dipyridamole in?

aspirin and dipyridamole belongs to the Nonsteroidal Anti-inflammatory Drug [EPC] class. See all Nonsteroidal Anti-inflammatory Drug [EPC] drugs at /class/nonsteroidal-anti-inflammatory-drug-epc.

What development phase is aspirin and dipyridamole in?

aspirin and dipyridamole is FDA-approved (marketed).

What are the side effects of aspirin and dipyridamole?

Common side effects of aspirin and dipyridamole include Headache, Dyspepsia, Abdominal pain, Nausea, Diarrhea. Serious adverse events: Cerebral hemorrhage, Intracranial hemorrhage, Subarachnoid hemorrhage, Gastric ulceration and perforation.

Related